300246 Guangdong Biolight Meditech
- 7.64
- -0.21-2.68%
Guangdong Biolight Meditech News
The China Securities Convertible Index opened down 0.02%. Among them, Shang Rong Convertible, Polaroid, Hangxin Convertible, Baichuan Transfer 2, and Jin Dan Convertible had the highest declines, falling 3.09%, 1.82%, 1.64%, 1.26%, and 1.1%, respectively.
The China Securities Convertible Index opened down 0.02%. Among them, Shang Rong Convertible, Polaroid, Hangxin Convertible, Baichuan Transfer 2, and Jin Dan Convertible had the highest declines, falling 3.09%, 1.82%, 1.64%, 1.26%, and 1.1%, respectively. In terms of growth, Kaineng Convertible Bonds, Tailin Convertible Bonds, Nootai Convertible Bonds, Mingdian Convertible Bonds, and Mingdian Transfer 02 had the highest gains, rising 13.74%, 10.38%, 1.15%, 1.1%, and 1.07%, respectively.
Paulette (300246.SZ): Has cumulatively repurchased 0.724% of shares
Glonghui, May 7, 丨 Paulette (300246.SZ) announced that as of April 30, 2024, the total number of shares repurchased by the company through centralized bidding transactions through a special stock repurchase account was 1,915,500 shares, accounting for 0.7240% of the company's total share capital; the highest transaction price of the repurchase was RMB 7.02 yuan/share, and the minimum transaction price was RMB 6.31 yuan/share, and the total amount paid was RMB 128,468.58 million (excluding transaction fees such as stamp duty and transaction fees
The China Securities Convertible Index rose 0.42% to 400.03, a new high since November 2023. Hangxin Convertible Bonds rose more than 17%, Haoneng and Mengsheng Bonds rose more than 13%, Secret Wei and Shang Rong Bonds rose more than 9%, and “Baichuan Tra
The China Securities Convertible Index rose 0.42% to 400.03, a new high since November 2023. Hangxin Convertible Bonds rose more than 17%, Haoneng and Mengsheng Bonds rose more than 13%, Secret Wei and Shang Rong Bonds rose more than 9%, and “Baichuan Transfer 2” and Polaroid Bonds rose more than 7%.
A-share afternoon review: The Shanghai index closed down 0.13%, and synthetic biology and low-altitude economic concepts had the highest gains
The main A-share index fell slightly. As of the midday close, the Shanghai Index fell 0.13% to 3136.62 points, the Shenzhen Stock Exchange Index fell 0.31%, and the GEM index fell 0.31%.
Express News | The medical device sector boosted Paulette's 20CM rise and stopped in early trading
Paulette (300246.SZ) announced its 2023 annual results, changing profit to loss to 65.1851 million yuan
According to the Zhitong Finance App, Paulette (300246.SZ) released its 2023 annual report. The company's revenue was 1,194 billion yuan, an increase of 0.87% over the previous year. The net loss attributable to shareholders of the listed company was 65.1851 million yuan. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 81.5033 million yuan, an increase of 1149.80% over the previous year. The basic loss per share was $0.247.
Express News | Paulette: Selected Hemodialysis Medical Consumables by Interprovincial Alliance for Centralized Volume Procurement
Paulette (300246.SZ) has been re-certified as a high-tech enterprise
Gelonghui, March 5 | Paulette (300246.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the Guangdong Provincial Taxation Bureau of the State Administration of Taxation. The certificate number is GR202344006246. The issuance period is December 28, 2023, and is valid for three years.
Paulette (300246.SZ): Proposed internal transfer of subsidiary shares
Gelonghui, March 4, 丨 Paulette (300246.SZ) announced that the company held the 13th meeting of the 8th board of directors on March 4, 2024 to review and pass the “Proposal on Internal Transfer of Subsidiary Shares”. The board of directors agreed that in order to further optimize the company's management structure, improve business management and operation efficiency, and reduce management costs, the company plans to integrate subsidiaries related to the blood purification consumables business in Tianjin to develop medical devices owned by the wholly-owned subsidiary Tianjin Baolite Technology Co., Ltd. (hereinafter referred to as “Tianjin Medical Baolite”) Co., Ltd. (hereinafter referred to as “Day”
Paulette (300246.SZ) plans to increase Tianjin Baolite's capital by 8.657 million yuan through debt-for-equity swaps
Paulette (300246.SZ) announced that the company plans to use debt-for-equity swaps to Tianjin Baolite Medical Technology Co., Ltd...
Paulette (300246.SZ): A total cost of 6.9097 million yuan to buy back 1,01.05 million shares
Glonghui, March 4, 丨 Paulette (300246.SZ) announced that as of February 29, 2024, the total number of shares repurchased by the company through centralized bidding transactions through the stock repurchase special securities account was 1,010.5 million shares, accounting for 0.3784% of the company's total share capital; the highest transaction price of the repurchase was RMB 7.02 yuan/share, the minimum transaction price was RMB 6.76 yuan/share, and the total transaction amount was RMB 690.097 million (excluding transaction fees such as stamp duty and transaction fees).
Paulette (300246.SZ): Initial repurchase of 25,600 shares involving 175.45 million yuan
Glonghui, Feb. 29 | Paulette (300246.SZ) announced that on February 28, 2024, the company repurchased the company's shares for the first time through a dedicated stock repurchase securities account. The number of repurchases was 25,600 shares, accounting for 0.0097% of the company's total share capital; the highest transaction price of the repurchase was RMB 6.88 yuan/share, and the minimum transaction price was RMB 6.84 yuan/share, and the total transaction amount was RMB 175.45 million (excluding transaction fees such as stamp duty and transaction fees).
Paulette (300246.SZ): Plans to spend 20 to 30 million yuan to buy back shares
Glonghui, Feb. 7 | Paulette (300246.SZ) announced that the company plans to repurchase shares for employee stock ownership plans or equity incentives. The total amount of capital to be used for the repurchase shall not be less than RMB 20.00 million (inclusive) and not more than RMB 30 million (inclusive). The price range to be repurchased does not exceed RMB 12 per share (inclusive). Based on the upper limit of the proposed repurchase price and the repurchase amount range, the number of repurchases was 1.666,700 to 2.5 million shares, accounting for 0.63% to 0.94% of the company's total share capital. This repurchase is actually used for employee stock ownership plans or equity incentives
Express News | Paulette: Net profit loss of 44 million yuan to 66 million yuan is expected to change year-on-year loss in 2023
The electrocardiograph was reported to be of poor quality Paulette: It is the company's low-end product
① Recently, an electrocardiograph produced by Paulette was notified by the State Drug Administration because it did not meet the standard requirements. ② Paulette said that the product in question is a low-end product of the company, and corresponding rectification measures have been formulated and completed in accordance with the requirements of relevant departments.
Baolite (300246.SZ) released results for the first three quarters, with net profit of 64.2788 million yuan, an increase of 529.58% over the previous year
Baolite (300246.SZ) released its report for the third quarter of 2023. The company achieved operating income of 9 in the first three quarters...
Paulette (300246.SZ): Products such as hemodialysis equipment, dialysis machines, and dialysis fluid filters have been sold abroad
Glonghui, September 21丨The Paulette (300246.SZ) agency said during research that hemodialysis products are sold abroad. For example, the company's hemodialysis equipment, dialysis devices, dialysis fluid filters and other products have already been sold abroad.
Baolite (300246.SZ): 889,700 owned shares will be listed and distributed on September 22
GLONGHUI September 20 | Paulette (300246.SZ) announced that the number of incentive recipients who met the vesting conditions is 107; the number of shares to be vested this time is 8897.17 million shares, accounting for 0.3374% of the company's current total share capital. The listing and circulation date of the shares currently owned is September 22, 2023 (Friday).
Paulette (300246.SZ): Controlling shareholders, actual controllers, directors, and senior managers promise not to reduce their holdings of the company's shares
GLONGHUI, September 14: Paulette (300246.SZ) announced that it has recently received a “Letter of Commitment on Not Reducing Company Shares” jointly issued by the company's controlling shareholder, actual controller, chairman and president, Mr. Yan Jinyuan, director and vice president, Mr. Liang Jin, director and vice president, Mr. Tang Wenpu, director of directors, Mr. Yang Yongxing, and financial director Ms. Xu Wei. The company's controlling shareholders, actual controllers, directors and senior managers who hold the company's shares have promised not to be within 6 months from September 14, 2023 Reduce your holdings in any way Company shares held; commitments
Baolite (300246.SZ) obtained 2 medical device registration certificates
Baolite (300246.SZ) announced that the company recently obtained 2 “Medical...” issued by the Guangdong Drug Administration
Analysis
Price Target
No Data
